AstraZeneca invests $3.5 billion in R&D and manufacturing in the United States
AstraZeneca today announces $3.5 billion of capital investment in the United States focused on expanding the Company’s research and manufacturing footprint by the end of 2026. This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs contributing to the growth of the US economy.
AstraZeneca’s expanding footprint in the US includes, among others:
- A state-of-the-art R&D centre in Kendall Square, Cambridge, Massachusetts
- A next generation manufacturing facility for biologics in Maryland
- Cell therapy manufacturing capacity on the West and East Coasts
- Specialty manufacturing in Texas
Pascal Soriot, Chief Executive Officer, AstraZeneca said: “Our multibillion dollar investment reflects the attractiveness of the business environment together with the quality of talent and innovation capabilities here in the United States. By expanding our R&D and manufacturing footprint, we aim to enhance the development of cutting-edge therapies and support the United States leadership in healthcare innovation.”
Delivering growth: Ambition 2030
These US investments are the first of a series of important steps to help deliver AstraZeneca’s ambition to achieve $80 billion in Total Revenue by 2030 as set out in May this year. A key element of our strategy is accelerating the Company’s development in the United States. The US is AstraZeneca’s largest market, generating 44% of its Total Revenue.1
AstraZeneca in the US
AstraZeneca has approximately 17,800 employees working across 17 R&D, manufacturing and commercial sites spanning 12 states.
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
References
- As at Q3 2024 noted in AstraZeneca Q3 Financial Results. Available at: https://www.astrazeneca.com/media-centre/press-releases/2024/9m-and-q3-2024-results.html. Accessed November 2024.
Adrian Kemp
Company Secretary
AstraZeneca PLC
View source version on businesswire.com: https://www.businesswire.com/news/home/20241111540981/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hanshow Showcases Retail Media and Store Intelligence at 2025 CGF Global Summit19.6.2025 17:00:00 CEST | Press release
Hanshow, a global leader in digital retail solutions, underscored its leadership in AI, IoT, and Retail Media at the 2025 Global Summit of the Consumer Good Forum (CGF), held from June 11 to 13 at RAI Amsterdam. From an immersive ‘Future Store’ showcase in the I-Zone to moderating one of the Summit’s most anticipated panel discussions, Hanshow demonstrated how its integrated platform is driving the next wave of store transformation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250619798164/en/ Inside the Future Store: Hanshow’s Real-Time Innovation at I-Zone At Booth No.8 in the I-Zone, Hanshow presented an interactive showcase themed “Powering Your Future Store,” highlighting four core pillars of the future store: real-time pricing and shelf operations powered by ESLs; smart carts that enhance the shopping experience with autonomous navigation and seamless checkout; GenAI-enabled journeys offering contextual promotions an
Grid Dynamics to Unveil Robotic Inspection Solution at Automatica 202519.6.2025 15:15:00 CEST | Press release
Key Takeaways: At Automatica 2025, Grid Dynamics will present TPGen—an AI robotic solution developed in partnership with Wandelbots to automate industrial robotic workflows that involve complex programming. The new solution dramatically reduces programming time—transforming what typically takes weeks of manual robot programming and analysis into automated processes completed in minutes through automatic tool-path generation based on CAD models. TPGen is built on top of the Wandelbots NOVA platform which enables seamless integration with a broad range of robotic manipulators. Grid Dynamics Holdings, Inc. (Nasdaq: GDYN) (Grid Dynamics)—a leading provider of technology consulting, platform and product engineering, AI, and digital‑engagement services—today announced it will showcase its TPGen robotic solution at Automatica 2025, the world's leading event for smart automation and robotics taking place in Munich, Germany from June 24-27, 2025. The TPGen solution from Grid Dynamics, developed
Experian Accelerates Migration to AWS to Drive Innovation with Generative AI19.6.2025 15:00:00 CEST | Press release
Global data and technology leader expands its cloud footprint to enhance performance and reliability, using AWS analytics and AI capabilities to give financial organizations access to real-time intelligence Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company (NASDAQ: AMZN), today announced that Experian, a global data and technology company, is embarking on the next phase of its cloud migration and has selected AWS as its preferred cloud. By leveraging AWS’s advanced cloud capabilities, Experian can provide faster, more scalable solutions that empower clients with deeper insights and more secure data services. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250619029263/en/ Experian's cloud first strategy, in partnership with AWS, accelerates innovation by enhancing performance, scalability, and reliability, while enabling the company to better serve its clients with innovative products and solutions. By migrating of
Greenland Resources Receives 30-Year Exploitation License for Molybdenum and Magnesium19.6.2025 14:52:00 CEST | Press release
Greenland Resources Inc. (Cboe CA: MOLY | FSE: M0LY) and its fully owned Greenlandic subsidiary Greenland Resources A/S (“Greenland Resources” or the “Company”) is pleased to announce that today the Greenland’s Minister for Business, Mineral Resources, Energy, Justice and Gender Equality, Naaja H. Nathanielsen, together with Dr. Ruben Shiffman, Chairman of the Board of Directors of Greenland Resources, signed a 30-year exploitation permit for molybdenum and magnesium for the Company’s Malmbjerg project in east Greenland (now defined as the Piiaaffik Høstakken). The Company can apply to extend the licence period up to 50-years. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250619915614/en/ Naalakkersuisut's Minister for Business, Mineral Resources, Energy, Justice and Gender Equality, Naaja H. Nathanielsen, stated at the handover ceremony: "It is with great satisfaction that the Greenland Government can grant another exploit
Ares Management Launches First ELTIF to Expand Access to European Direct Lending Strategy19.6.2025 12:00:00 CEST | Press release
Ares Management Corporation (NYSE: ARES) (“Ares”), a leading global alternative investment manager, announced today the launch of its first European Long-Term Investment Fund (“ELTIF”) vehicle, the Ares European Strategic Income ELTIF Fund (“AESIF ELTIF”), a semi-liquid perpetual direct lending fund that will provide individual investors in the European Economic Area with expanded access to Ares’ leading European Direct Lending strategy. AESIF ELTIF is the latest offering through the wealth channel and its first under the updated ELTIF regime. Designed to deliver a diversified portfolio largely comprising directly originated, senior secured floating rate loans to businesses in Western Europe, AESIF ELTIF seeks to provide a durable income solution with downside protection and yield stability. AESIF ELTIF is intended to widen individual investor participation in Ares’ European Direct Lending strategy through lower investment minimums relative to traditional alternative investment product
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom